SCHEMBL625592

SCHEMBL625592

C=CCn1cnc2ccc(N)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
HSD17B10 Q99714 1/20 0.47
EGFR P00533 1/20 0.46
SLC2A1 P11166 1/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DDB1 Q16531 2/20 0.37
CRBN Q96SW2 2/20 0.37
IKZF3 Q9UKT9 2/20 0.37
FGFR1 P11362 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PRKCI P41743 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
RAD52 P43351 1/20 0.34
ERBB2 P04626 1/20 0.34
QPCT Q16769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623907 0.87 MAPT (0.64) MAPTHSD17B10EGFRSLC2A1KDM4E
SCHEMBL19848085 0.81 TNF (0.44) MAPTHSD17B10KDM4EALDH1A1HPGD
SCHEMBL19911437 0.81 TBXA2R (0.41) EGFRSLC2A1KDM4ETDP1QPCT
SCHEMBL6128998 0.79 POLB (0.43) MAPTHSD17B10ALDH1A1RAB9AFGFR1
SCHEMBL19911423 0.78 MAPT (0.51) MAPTHSD17B10KDM4EDDB1CRBN
SCHEMBL15910681 0.78 MAPT (0.51) MAPTHSD17B10KDM4EALDH1A1HPGD
SCHEMBL19848346 0.77 BRD4 (0.44) QPCT
SCHEMBL7128052 0.77 MTNR1A (0.54) MAPTHSD17B10KDM4EALDH1A1HPGD
SCHEMBL10896310 0.77 PRPS1 (0.45) KDM4EALDH1A1QPCT
SCHEMBL11234727 0.77 POLB (0.36) MAPTHSD17B10ALDH1A1FGFR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
EP-3279997-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2018-02-07 EP disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 MAPT 4759/4885HSD17B10 33/4885EGFR 2619/4885
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 MAPT 1283/4885HSD17B10 2395/4885EGFR 3714/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 MAPT 4794/4885HSD17B10 1003/4885EGFR 317/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 MAPT 1283/4885HSD17B10 2395/4885EGFR 3714/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 MAPT 4794/4885HSD17B10 1003/4885EGFR 317/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 MAPT 4691/4885HSD17B10 874/4885EGFR 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.